The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations

被引:32
作者
Hucke, Anna [1 ]
Ciarimboli, Giuliano [1 ]
机构
[1] Munster Univ Hosp, Expt Nephrol, Med Clin D, Albert Schweitzer Campus 1-A14, D-48149 Munster, Germany
关键词
transporters; chemotherapeutic drugs; toxicity; side effects; CISPLATIN-INDUCED NEPHROTOXICITY; MESSENGER-RNA EXPRESSION; RENAL TUBULAR CELLS; TOXIN EXTRUSION; COPPER TRANSPORTER; OCT-1; ACTIVITY; CELLULAR ACCUMULATION; SUBSTRATE-SPECIFICITY; ANION TRANSPORTER-3; IMATINIB MESYLATE;
D O I
10.1002/jcph.706
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The introduction of chemotherapy in the treatment of cancer is one of the most important achievements of modern medicine, even allowing the cure of some lethal diseases such as testicular cancer and other malignant neoplasms. The number and type of chemotherapeutic agents available have steadily increased and have developed until the introduction of targeted tumor therapy. It is now evident that transporters play an important role for determining toxicity of chemotherapeutic drugs not only against target but also against nontarget cells. This is of special importance for intracellularly active hydrophilic drugs, which cannot freely penetrate the plasma membrane. Because many important chemotherapeutic agents are substrates of transporters for organic cations, this review discusses the known interaction of these substances with these transporters. A particular focus is given to the role of transporters for organic cations in the development of side effects of chemotherapy with platinum derivatives and in the efficacy of recently developed tyrosine kinase inhibitors to specifically target cancer cells. It is evident that specific inhibition of uptake transporters may be a possible strategy to protect against undesired side effects of platinum derivatives without compromising their antitumor efficacy. These transporters are also important for efficient targeting of tyrosine kinase inhibitors to cancer cells. However, in order to achieve the aims of protecting from undesired toxicities and improving the specificity of uptake by tumor cells, an exact knowledge of transporter expression, function, regulation under normal and pathologic conditions, and of genetically and epigenetically regulation is mandatory.
引用
收藏
页码:S157 / S172
页数:16
相关论文
共 178 条
[1]   The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons [J].
Adelsberger, H ;
Quasthoff, S ;
Grosskreutz, J ;
Lepier, A ;
Eckel, F ;
Lersch, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :25-32
[2]   Interventions for preventing neuropathy caused by cisplatin and related compounds [J].
Albers, James W. ;
Chaudhry, Vinay ;
Cavaletti, Guido ;
Donehower, Ross C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02)
[3]   Renal ontogeny of ifosfamide nephrotoxicity [J].
Aleksa, K ;
Halachmi, N ;
Ito, S ;
Koren, G .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 144 (06) :285-293
[4]  
Amptoulach Sousana, 2011, Chemother Res Pract, V2011, P843019, DOI 10.1155/2011/843019
[5]   Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells [J].
Arimany-Nardi, C. ;
Montraveta, A. ;
Lee-Verges, E. ;
Puente, X. S. ;
Koepsell, H. ;
Campo, E. ;
Colomer, D. ;
Pastor-Anglada, M. .
PHARMACOGENOMICS JOURNAL, 2015, 15 (04) :363-371
[6]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[7]   Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants [J].
Badagnani, Ilaria ;
Castro, Richard A. ;
Taylor, Travis R. ;
Brett, Claire M. ;
Huang, Conrad C. ;
Stryke, Douglas ;
Kawamoto, Michiko ;
Johns, Susan J. ;
Ferrin, Thomas E. ;
Carlson, Elaine J. ;
Burchard, Esteban G. ;
Giacomini, Kathleen M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (02) :521-529
[8]   Common Drugs Inhibit Human Organic Cation Transporter 1 (OCT1)-Mediated Neurotransmitter Uptake [J].
Boxberger, Kelli H. ;
Hagenbuch, Bruno ;
Lampe, Jed N. .
DRUG METABOLISM AND DISPOSITION, 2014, 42 (06) :990-995
[9]  
BREGMAN CL, 1986, CANCER CHEMOTH PHARM, V18, P117
[10]   Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) [J].
Burger, H. ;
Zoumaro-Djayoon, A. ;
Boersma, A. W. M. ;
Helleman, J. ;
Berns, E. M. J. J. ;
Mathijssen, R. H. J. ;
Loos, W. J. ;
Wiemer, E. A. C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (04) :898-908